Abstract:Abstract Background Smoldering multiple myeloma (SMM), an asymptomatic precursor of multiple myeloma (MM), carries a variable risk of progression to MM. There is little consensus on the efficacy or optimal timing of treatment in SMM. We systematically reviewed the landscape of all clinical trials in SMM. We compared the efficacy of treatment regimens studied in SMM to results from these regimens when used in newly diagnosed multiple myeloma (NDMM), to determine whether the data suggest deeper responses in SMM versus NDMM. Methods All prospective interventional clinical trials for SMM, including published studies, meeting abstracts, and unpublished trials listed on ClinicalTrials.gov up to April 1, 2023, were identified. Trial-related variables were captured, including treatment strategy and efficacy results. Relevant clinical endpoints were defined as overall survival (OS) and quality of life. Results Among 45 SMM trials identified, 38 (84.4%) assessed active myeloma drugs, while 7 (15.6%) studied bone-modifying agents alone. Of 18 randomized trials in SMM, only one (5.6%) had a primary endpoint of OS; the most common primary endpoint was progression-free survival (n = 7, 38.9%). Among 32 SMM trials with available results, 9 (28.1%) met their prespecified primary endpoint, of which 5 were single-arm studies. Six treatment regimens were tested in both SMM and NDMM; 5 regimens yielded a lower rate of very good partial response rate or better (≥VGPR) in SMM compared to the corresponding NDMM trial (32% vs 63%, 43% vs 53%, 40% vs 63%, 86% vs 89%, 92% vs 95%, and 94% vs 87%, respectively). Conclusion In this systematic review of all prospective interventional clinical trials in SMM, we found significant variability in trial design, including randomization status, primary endpoints, and types of intervention used. Despite the statistical limitations, comparison of treatment regimens revealed no compelling evidence that the treatment is more effective when introduced early in SMM compared to NDMM.

Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma

Mode of progression in smoldering multiple myeloma: a study of 406 patients

Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer

Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper

Evaluating early intervention in smoldering myeloma clinical trials: a systematic review

Smoldering multiple myeloma current treatment algorithms

Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation

Smoldering Multiple Myeloma: Observation Versus Control Versus Cure

The Difficulty in Defining the True High-Risk Smoldering Myeloma

Multiple myeloma, immunotherapy and minimal residual disease

Smoldering Multiple Myeloma : Taking the narrow over the wide path?

Stromal alterations in patients with MGUS, smoldering myeloma and multiple myeloma

How to Identify and Manage High-Risk Smoldering Multiple Myeloma

Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)

Progress and Paradigms in Multiple Myeloma

Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma—A Retrospective Multicenter Analysis